SS Innovations International Inc. (NASDAQ: SSII) has announced the launch of Sri Lanka’s first robotic cardiac surgery program at Kings Hospital Colombo, utilizing the company’s SSi Mantra 3.0 surgical robotic system. The inaugural procedure was a robotic-assisted left internal mammary artery (LIMA) takedown, performed by Dr. Sudhir Srivastava, founder and chairman of SS Innovations, alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. This milestone was highlighted in a recent company video describing the program’s early activity.
The introduction of robotic cardiac surgery in Sri Lanka represents a significant advancement in the country’s healthcare capabilities, potentially offering patients less invasive surgical options, reduced recovery times, and improved outcomes. The program’s rapid uptake—Kings Hospital has completed more than 25 robotic procedures in just three weeks—demonstrates strong local adoption and the potential for broader regional expansion. This is particularly important for Sri Lanka, where access to advanced surgical technologies has historically been limited.
SS Innovations’ expansion into Sri Lanka is part of a larger global growth trajectory. As of the end of the second quarter, the company reported 224 cumulative SSi Mantra installations across 12 countries. Second-quarter revenue reached $13.9 million, while robotic procedures increased 143% year over year to 2,528, indicating rising utilization of the installed base. These figures suggest that the company’s robotic systems are not only being adopted but are also being used frequently, which is critical for long-term revenue sustainability and clinical validation.
The next major corporate milestone for SS Innovations is regulatory expansion. The company is actively pursuing U.S. Food and Drug Administration (FDA) clearance and European CE marking for the SSi Mantra system. Achieving these certifications would open up two of the world’s largest and most lucrative medical device markets, significantly amplifying the company’s addressable market and competitive positioning. Success in these regulatory endeavors could also accelerate partnerships with major hospitals and healthcare systems globally.
For investors, the launch in Sri Lanka and the company’s operational metrics underscore SS Innovations’ potential to disrupt the surgical robotics market, which has traditionally been dominated by a few large players. The company’s ability to deploy its technology in diverse geographies and achieve high procedure volumes suggests a scalable business model. However, regulatory approvals remain a key catalyst to watch, as they will determine the pace of expansion into high-value markets.
The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII. For more information on TechMediaWire, visit https://www.TechMediaWire.com. Full terms of use and disclaimers are available at https://www.TechMediaWire.com/Disclaimer.
